IP Library Granted Patent US 8,551,756
Granted Patent B2
US 8,551,756 · App. 12/689,826 · Granted Oct 8, 2013

Avian influenza chimeric VLPS

Inventors: Gale Smith (Rockville, MD); Peter Pushko (Frederick, MD)
Assignee: Novavax, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,551,756
App. No.
12/689,826
Granted
Oct 8, 2013
Kind
B2
Abstract

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

Claims (17)

1. A method of increasing the efficiency of influenza virus-like particle (VLP) production comprising expressing an avian influenza matrix (M1) protein and at least one non-avian influenza protein in a host cell,

wherein the avian influenza M1 protein is derived from A/Indonesia/5/05 influenza, and

whereby increased VLP production is obtained in the host cell comprising the avian influenza M1 protein compared to a host cell expressing a non-avian influenza M1 protein.

2. The method of claim 1 , wherein said A/Indonesia/5/05 M1 protein comprises the amino acid sequence of SEQ ID NO: 3.

3. The method of claim 1 , wherein said non-avian influenza protein is an influenza hemagglutinin (HA) protein.

4. The method of claim 3 , wherein said influenza HA protein is derived from a strain of seasonal influenza virus.

5. The method of claim 3 , wherein said influenza HA protein has hemagglutinin activity.

6. The method of claim 3 , wherein said influenza HA protein is a chimeric protein.

7. The method of claim 6 , wherein said chimeric protein comprises the external domain of non-avian influenza HA protein fused to the transmembrane and/or cytoplasmic terminal domains of an avian influenza HA protein.

8. The method of claim 7 , wherein said avian influenza HA protein is derived from influenza strain A/Indonesia/5/05.

9. The method of claim 1 , wherein said non-avian influenza protein is an influenza neuraminidase (NA) protein.

10. The method of claim 9 , wherein said influenza NA protein is derived from a strain of seasonal influenza virus.

11. The method of claim 9 , wherein said influenza NA protein has neuraminidase activity.

12. The method of claim 9 , wherein said influenza NA protein is a chimeric protein.

13. The method of claim 12 , wherein said chimeric protein comprises the external domain of non-avian influenza NA protein fused to the transmembrane and/or cytoplasmic terminal domains of an avian influenza NA protein.

14. The method of claim 13 , wherein said avian influenza NA protein is derived from influenza strain A/Indonesia/5/05.

15. The method of claim 1 , wherein said host cell is selected from the group consisting of yeast, insect, amphibian, avian, and mammalian cells.

Assignments (2)
SECURITY INTEREST Recorded Feb 25, 2026
From: NOVAVAX, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 074976/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2010
From: SMITH, GALE; PUSHKO, PETER
To: NOVAVAX, INC.
Reel/Frame 024134/0286 →
Continuity (6)
Continuation PCTUS2008070638 · Jul 21, 2008
Continuation In Part 10617569 · Jul 11, 2003
Provisional Application 60950707 · Jul 19, 2007
Provisional Application 60970592 · Sep 7, 2007
Provisional Application 61071835 · May 20, 2008
Related Publication 20100184192A1 · Jul 22, 2010